

KILITCH DRUGS INDIA LIMITED
Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter and Nine Month ended 31st December 2012

PART I	Particulars	STAND ALONE						CONSOLIDATED			
		Unaudited						Audited	Unaudited		Audited
		Quarter ended			Nine Month Ended			Year ended	Nine Month Ended		Year ended
		31st December 2012	30th September 2012	30th June 2012	31st December 2011	31st December 2012	31st December 2011	31st March 2012	31st December 2012	31st December 2011	31st March 2012
1	Income from operations										
	(a) Net Sales/Income from operations (net of Excise)	344.88	589.44	1,481.43	2,741.91	2,415.75	9,052.93	10,685.99	2,590.35	9,124.98	10,796.35
	(b) Other operating income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations (Net)	344.88	589.44	1,481.43	2,741.91	2,415.75	9,052.93	10,685.99	2,590.35	9,124.98	10,796.35
2	Expenses										
	(a) Cost of materials consumed	157.91	406.14	1,391.44	1,615.94	1,555.49	5,744.85	7,058.99	2,026.75	5,753.17	7,059.27
	(b) Purchased of Stock-in-trade										
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	23.39	120.60	-119.54	92.51	24.45	-203.82	135.13	41.12	-210.01	125.02
	(d) Employee benefits expenses	106.72	60.20	59.23	134.75	226.16	429.83	499.78	344.53	563.57	644.46
	(e) Depreciation and amortisation expenses	32.83	32.81	32.81	105.69	68.45	385.69	483.37	100.43	385.69	487.35
	(f) Other expenses (Any item exceeding 10% of the expenses relating to continuing operations to be shown separately)	167.77	196.45	142.37	311.75	508.59	1,130.90	1,575.64	601.12	1,197.34	1,703.99
	Total Expenses	488.62	818.29	1,506.31	2,310.64	2,613.14	7,487.56	9,752.91	3,113.99	7,689.78	10,021.09
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	-143.74	-228.76	-24.88	431.27	-397.39	1,665.38	933.08	-514.81	1,435.22	775.25
4	Other Income	207.19	254.74	328.67	6.28	791.60	31.60	110.25	800.78	31.6	105.19
5	Profit / (Loss) from ordinary activities before finance cost and exceptional items (3+4)	63.45	25.98	304.79	437.56	394.21	1,696.98	1,043.33	286.17	1,466.82	880.39
6	Finance Costs	0.00	4.19	2.97	112.89	7.16	234.84	295.33	7.16	234.84	296.1
7	Profit / (Loss) from ordinary activities after finance cost but before exceptional items (5-6)	63.45	21.79	301.82	324.66	387.05	1,362.14	748.00	279.01	1,231.98	584.29
8	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	-1,552.82	0.00	0	-1,552.82
9	Profit / (Loss) from ordinary activities before tax (7+8)	63.45	21.79	301.82	324.66	387.05	1,362.14	-804.82	279.01	1,231.98	-968.53
10	Tax Expenses	0.00	2.00	52.09	52.09	2.00	280.00	2,305.00	2.00	280	2,105.18
11	Net Profit / (Loss) from ordinary activities after tax (9-10)	63.45	19.79	301.82	272.57	385.05	1,102.14	-2,369.82	277.01	971.98	-3073.71
12	Extra Ordinary Items (net of tax expenses Rs. Lakhs)	0.00	0.00	0.00	0.00	0.00	0.00	10,704.79	0.00	0	10,704.79
13	Net Profit / (Loss) for the period (11+12)	63.45	19.79	301.82	272.57	385.05	1,102.14	7,794.97	277.01	971.98	7,631.08
14	Share of Profit / (Loss) of associates*										
15	Minority Interest*										
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18	1323.18
17	Paid-Up equity share capital (Face Value of the Share shall be indicated)										
18	Reserve excluding Revaluation Reserve as per Balance sheet of previous accounting year										
19	Earnings per share (before extra ordinary items) (of Rs. 10 /-each) (not annualised):										
	(a) Basic	0.48	0.15	2.28	2.06	2.91	8.33	-21.99	2.08	7.35	-23.23
	(b) Diluted	0.44	0.14	2.08	2.01	2.65	7.59	-21.99	2.04	6.70	-23.23
20	Earnings per share (after extra ordinary items) (of Rs. 10 /-each) (not annualised):										
	(a) Basic	0.48	0.15	2.28	2.25	2.91	8.33	58.90	2.08	7.35	57.67
	(b) Diluted	0.44	0.14	2.06	2.20	2.65	7.6	53.88	2.04	6.70	52.55

See accompanying note to the financial results




PART II	Particulars	STAND ALONE					CONSOLIDATED				
		31st December 2012	30th September 2012	30th June 2012	31st December 2011	31st December 2012	31st December 2011	31st March 2012	30th September 2012	30th September 2011	31st March 2012
A	PARTICULARS OF SHAREHOLDING										
	1) Public shareholding										
	Number of shares	4706393	4706393	4706393	4706393	4706393	4706393	4706393	4706393	4706393	4706393
	Percentage of shareholding	35.57	35.57	35.57	35.57	35.57	35.57	35.57	35.57	35.57	35.57
	2) Promoters and Promoter Group Shareholding **										
	a) Pledge / Encumbered										
	Number of shares										
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)										
	Percentage of shares (as a % of the total share capital of the company)										
	b) Non-encumbered										
Number of shares	8525435	8525435	8525435	8525435	8525435	8525435	8525435	8525435	8525435	8525435	
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	
Percentage of shares (as a % of the total share capital of the company)	64.43	64.43	64.43	64.43	64.43	64.43	64.43	64.43	64.43	64.43	

Particulars	3 months ended 31st December 2012
5) INVESTOR COMPLAINTS	
Pending at the beginning of the Quarter	NIL
Received during the Quarter	36
Disposed of during the Quarter	36
Remaining unrecieved at the end of the Quarter	NIL

- i) The above results after being review by the audit committee have been approved and taken on record by the board of Directors at its meeting held on 12th February 2013 and are subject to limited review by the auditors
- ii) During the Financial year 2012-2013, the main manufacturing activity of the Company has substantially reduced, as the Company has moved out under PTA Agreement majority of its products to Akorn India Private Limited.
- iii) Results of the quarter ended December 2011, include operations of HP plant which was sold to M/s Akorn India Private Limited on slump sale basis on 28th February 2012
- iv) Other Income consists of dividends received from Mutual funds of Rs. 196.03 lakhs for the quarter ended 31st December 2012
- v) On 21/09/2012, 66,29,342 Equity shares (50.10%) of the Company was acquired by Kiltch Pharma (Co) Ltd (a company in which the Directors are substantially interested)
- vi) The Company has only one primary reportable segment-Pharmaceuticals
- vii) The previous year/period figures have been regrouped and reclassified wherever required to conform with current year/period figures

Mumbai
 Dated : 12th February 2013.

For Kiltch Drugs (India) Ltd.
 Mukund Mehta
 Managing Director



M/S R N R IYER & CO., Chartered Accountants.

No 10 Vaishak, 2B P.K.Road, Nahur, Mulund west, Mumbai – 400080.

Tel: 022-25643138, E-mail: rnrriyerca@fastmail.fm

Review Report to the Board of Directors of M/s Kilitch Drugs India Limited

We have reviewed the accompanying statement of un-audited financial results of M/s. Kilitch Drugs India Limited for the quarter ended 31st December, 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of the Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures, applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the Accounting Standards referred to in Section 211 (3C) of the Companies Act, 1956 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with Stock Exchanges including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s R N R Iyer & Co.,

Chartered Accountants

Firm registration no 103786W



(Rajkumar Iyer)

(Proprietor)

Membership No 33964

Mumbai

Dated: 12th February, 2013

